N-[6-(4-Butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide

ID: ALA3325891

Chembl Id: CHEMBL3325891

PubChem CID: 66575899

Max Phase: Preclinical

Molecular Formula: C28H31ClN8O3

Molecular Weight: 563.06

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCCC(=O)c1cnn(-c2ccc(NC(=O)c3cn(CC(=O)N4CCN(C)CC4)c4ccc(Cl)cc34)nn2)c1C

Standard InChI:  InChI=1S/C28H31ClN8O3/c1-4-5-24(38)21-15-30-37(18(21)2)26-9-8-25(32-33-26)31-28(40)22-16-36(23-7-6-19(29)14-20(22)23)17-27(39)35-12-10-34(3)11-13-35/h6-9,14-16H,4-5,10-13,17H2,1-3H3,(H,31,32,40)

Standard InChI Key:  BJGNAIOOAINEET-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA3325891

   N-[6-(4-butanoyl-5-methylpyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]indole-3-carboxamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 563.06

Molecular Weight (Monoisotopic): 562.2208

AlogP: 3.59

#Rotatable Bonds: 8

Polar Surface Area: 118.25

Molecular Species: NEUTRAL

HBA: 9

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: ┄

CX Basic pKa: 6.96

CX LogP: 2.94

CX LogD: 2.80

Aromatic Rings: 4

Heavy Atoms: 40

QED Weighted: 0.33

Np Likeness Score: -2.06

References

1. Boldron C, Besse A, Bordes MF, Tissandié S, Yvon X, Gau B, Badorc A, Rousseaux T, Barré G, Meneyrol J, Zech G, Nazare M, Fossey V, Pflieger AM, Bonnet-Lignon S, Millet L, Briot C, Dol F, Hérault JP, Savi P, Lassalle G, Delesque N, Herbert JM, Bono F..  (2014)  N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.,  57  (17): [PMID:25075638] [10.1021/jm500588w]

2. Ma BB, Montgomery AP, Chen B, Kassiou M, Danon JJ..  (2022)  Strategies for targeting the P2Y₁₂ receptor in the central nervous system.,  71  [PMID:35640763] [10.1016/j.bmcl.2022.128837]

3. Al-Najjar BO, Saqallah FG, Abbas MA, Al-Hijazeen SZ, Sibai OA..  (2022)  P2Y₁₂ antagonists: Approved drugs, potential naturally isolated and synthesised compounds, and related in-silico studies.,  227  [PMID:34731765] [10.1016/j.ejmech.2021.113924]

Source

Source(1):

• Scientific Literature